Is it more of a risk to take bio identical HRT or to take nothing and face other risks

The short answer: the evidence shows bioidentical HRT helps some symptoms, but is too thin to tell you whether the overall risk of taking it is bigger or smaller than the risk of taking nothing.

Let me start with what the records actually cover. The most relevant study, a 2011 observational cohort of 296 women, found that compounded bioidentical HRT reduced moderate-to-severe mood symptoms by about 25 to 30 percentage points within 3 to 6 months—irritability dropped from 58% to 33%, anxiety from 49% to 27%, emotional lability from 53% to 28% [1]. That is a real improvement in how people feel. But the same study found no significant reduction in hot flashes or night sweats [1]. And the safety data was essentially absent: only 62 women had any documented follow-up for heart attacks or breast cancer, covering just 117 person-years. The authors themselves say the sample is too small for firm safety conclusions [1].

The bigger picture from other records is mixed. A 2017 Cochrane review found that combination hormone therapy raised the risk of breast cancer from about 19 per 1000 to 24 per 1000, and venous thromboembolism from 2 to 7 per 1000 [6]. But those numbers come from studies using synthetic hormones, not bioidenticals. The difference matters. A 2024 JAMA study linked historical hormone therapy use to lower all-cause mortality (hazard ratio 0.92) and a younger biological aging profile, but that covers all types of hormones, not bioidenticals specifically [7]. A Finnish study of nearly 500,000 women found estradiol-based therapy was tied to lower mortality from heart disease [3]. A 2014 study found transdermal (skin-patch) hormones had no higher heart risks than oral ones [4].

Here is the table pulling together the major absolute risks from the Cochrane review [6]:

The problem is that these numbers come from studies of synthetic conjugated equine estrogens and medroxyprogesterone, not bioidentical 17β-estradiol and natural progesterone. The REPLENISH trial design from 2015 shows drug companies are now testing exactly that combination in rigorous placebo-controlled trials [2], but those results are not yet published in the records I have.

So here is the honest bottom line. For symptom relief, especially mood, the evidence is decent: women in the 2011 cohort who started bioidentical HRT reported feeling significantly better within months [1]. For long-term risks like breast cancer, blood clots, and heart disease, there is simply no adequate safety trial of compounded bioidentical HRT. The 2017 USPSTF review says not to use any hormone therapy for prevention in asymptomatic women [5], and that is the official consensus, but it does not settle the question for a woman who is having symptoms bad enough to seek treatment. She is not asymptomatic.

What you are really comparing is a known short-term benefit against an unknown long-term risk, with the best available data coming from studies of a different drug formulation. That is a genuinely uncertain trade-off.

My call: if severe menopausal symptoms are affecting your quality of life, the evidence supports trying bioidentical HRT for symptom relief. But do not assume it is harmless. The long-term safety data for these specific formulations simply does not exist at the scale needed for firm conclusions.

Confidence: low. The key trials have not been done.